AstraZeneca plc: Time To Cash In?

There are several reasons why Astra (LON:AZN) investors may want to cash in now, argues Alessandro Pasetti

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Put yourself in the shoes of an investor with a meaningful stake in AstraZeneca (LSE: AZN) (NYSE: AZN.US): the value of your holdings dropped 11% on Monday, while it’s virtually unchanged at about £42 on Tuesday.

AstraZeneca’s unaffected share price was £35.8 on 3 January. Your pre-tax paper gain is still a market-beating 17.3%.

There are several reasons why investors may be tempted to cash in now, although there remains a reasonable doubt that the deal might go through.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Profitability/Revenue

Between 2004 and 2010, Astra recorded a normalised growth rate of 18% for earnings before earnings before interest, taxes, depreciation and amortisation (EBITDA), but in the last four years cash flow has swiftly plummeted.

EBITDA — essentially operating cash flow adjusted by working capital, i.e. short-term cash items — has almost halved to less than £5 billion. According to market consensus estimates, revenue will decline by about 2% a year into 2016. Astra says its revenue will outpace market growth by 2023.

Growth

Assuming that Astra’s operating cash flow grows at a steady rate of 7% yearly, and assuming constant trading multiples, Pfizer (NYSE: PFE.US)’s latest proposal represents more than five years of growth for Astra.

A decent R&D pipeline and poor visibility into the next few years don’t justify a bullish stance on the stock – unless, that is, Pfizer is rejected and makes a comeback in six months.

Net Leverage/Free Cash Flow

Astra’s net leverage, as gauged by the net debt/EBITDA ratio, is low but rising. It stands at 0.6x, which isn’t unusual for big pharmaceutical companies. Its free-cash-flow yield is 5.5%. The payout has been flat at about $3.5bn in the last four years, for a current dividend yield of 3.5%.

The way it looks, Astra is an overpriced bond.

It needs a takeover premium to justify its current price.

M&A/Break-Up

Astra may be an obvious target for Pfizer, but other bidders are thin on the ground. One way to boost value, but also to heighten the investment risk profile of Astra, would be to become more acquisitive.

Astra is not an obvious break-up candidate, although one could argue for a separation of its R&D functions from sales and marketing in order to crystalise value all along the value chain. That’s easier said than done, however.

A large, debt-funded buyback would be accretive to earnings and would likely provide some support to Astra stock. That’s is an option management should consider along with a larger dividend.

Astra intends to preserve its credit rating and invest in the business to pursue long-term growth.

Valuation

This is the tricky bit. It’s unclear where trading multiples expansion will come from, particularly if growth sputters.

Astra’s trading multiples are still well above five-year highs. Astra will need shareholder-friendly activity to convince investors to stick with their bets. Management have a lot to do in the upcoming quarters to convince investors that they can beat estimates.

Managing expectations will be of paramount importance.

(For the record, everybody now has come to the conclusion that a bid in the region of £60 per share would be successful – just as we noted on May 6.)

But there may be an even bigger investment opportunity that’s caught my eye:

Investing in AI: 3 Stocks with Huge Potential!

🤖 Are you fascinated by the potential of AI? 🤖

Imagine investing in cutting-edge technology just once, then watching as it evolves and grows, transforming industries and potentially even yielding substantial returns.

If the idea of being part of the AI revolution excites you, along with the prospect of significant potential gains on your initial investment…

Then you won't want to miss this special report inside Motley Fool Share Advisor – 'AI Front Runners: 3 Surprising Stocks Riding The AI Wave’!

And today, we're giving you exclusive access to ONE of these top AI stock picks, absolutely free!

Get your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro does not own shares in any of the companies mentioned.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »